Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4
- PMID: 11586204
Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4
Abstract
Purpose: We evaluated differences in clinical and pathological outcomes between Gleason 3 + 4 and 4 + 3 prostate cancer.
Materials and methods: The radical prostatectomy whole mounted specimens from 263 men with pathological Gleason 7 tumors were identified. Gleason 3 + 4 and 4 + 3 tumors were compared in regard to pathological variables and outcome. Significance of clinical and pathological data on progression-free survival was analyzed.
Results: Of the tumors 34% had a primary Gleason grade of 4, and were more likely than those with primary grade 3 to have seminal vesicle involvement (34% versus 18%, p = 0.006), a higher pathological stage (pT3 55% versus 42%, N+ 13% versus 3%, 0.001), extraprostatic extension (58% versus 38%, 0.001) and higher median preoperative prostate specific antigen (PSA) (13.5 versus 9.0 ng./ml., respectively <0.001). Mean followup plus or minus standard deviation was 6.8 +/- 1.9 years. The overall 10-year crude, cancer specific and progression-free survival rates were 83%, 99% and 58%, respectively. Primary Gleason grade was significantly associated with progression-free (risk ratio 1.6, 95% confidence interval 1.08 to 2.5, p = 0.02) but not crude and cancer-specific survival. Univariately, primary Gleason grade 4 was associated with progression-free survival, as were percent Gleason 4, seminal vesicle invasion, lymph node involvement, pT stage, margin status, DNA ploidy, preoperative PSA, cancer volume and extent of extraprostatic extension. Multivariately, only preoperative PSA (p <0.001), seminal vesicle invasion (<0.001) and DNA ploidy (0.002) were associated with progression-free survival. Primary Gleason grade and percent Gleason 4 were not identified as independently associated with progression-free survival.
Conclusions: In patients with Gleason 7 score prostate cancer primary Gleason grade 3 and 4 cancers are different in pathological parameters and prognosis. However, primary Gleason grade does not provide any additional information than other known prognostic factors, such as preoperative PSA, seminal vesicle invasion and DNA ploidy.
Similar articles
-
Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.J Urol. 2001 Jan;165(1):119-25. doi: 10.1097/00005392-200101000-00030. J Urol. 2001. PMID: 11125379
-
Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables.J Urol. 2002 Jan;167(1):117-22. J Urol. 2002. PMID: 11743287
-
Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.J Urol. 2000 Nov;164(5):1596-600. J Urol. 2000. PMID: 11025712
-
Prognostic markers in clinically localized prostate cancer.Tech Urol. 1998 Mar;4(1):35-42. Tech Urol. 1998. PMID: 9568775 Review.
-
The use of percent free prostate specific antigen for staging clinically localized prostate cancer.J Urol. 1998 Apr;159(4):1238-42. J Urol. 1998. PMID: 9507844 Review.
Cited by
-
Prognostic factors for the development of biochemical recurrence after radical prostatectomy.Prostate Cancer. 2011;2011:485189. doi: 10.1155/2011/485189. Epub 2011 Jun 15. Prostate Cancer. 2011. PMID: 22110987 Free PMC article.
-
A narrowing range of bone scan in newly diagnosed prostate cancer patients: A retrospective comparative study.Urol Ann. 2015 Apr-Jun;7(2):193-8. doi: 10.4103/0974-7796.150479. Urol Ann. 2015. PMID: 25835063 Free PMC article.
-
Prognostic factors for failure after prostatectomy.J Cancer. 2010 Dec 7;2:1-19. J Cancer. 2010. PMID: 21197260 Free PMC article.
-
Mast cell density and the context of clinicopathological parameters and expression of p185, estrogen receptor, and proliferating cell nuclear antigen in gastric carcinoma.World J Gastroenterol. 2002 Dec;8(6):1005-8. doi: 10.3748/wjg.v8.i6.1005. World J Gastroenterol. 2002. PMID: 12439914 Free PMC article.
-
Biomarker research in prostate cancer--towards utility, not futility.Nat Rev Urol. 2011 Mar;8(3):131-8. doi: 10.1038/nrurol.2011.11. Nat Rev Urol. 2011. PMID: 21394176 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous